HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.109.066639v1 50/12/1927    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kayani, I. Articles by Bomanji, J. B. Search for Related Content PubMed PubMed Citation Articles by Kayani, I. Articles by Bomanji, J. B.

A Comparison of ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT in Pulmonary Neuroendocrine Tumors

¹ Institute of Nuclear Medicine, University College Hospital, UCLH, London, United Kingdom; ² Chest Medicine, Lister Hospital, Stevenage, United Kingdom; and ³ Department of Gastroenterology, Royal Free Hospital, London, United Kingdom

Correspondence: For correspondence or reprints contact: Jamshed Bomanji, Institute of Nuclear Medicine, University College Hospital, 235 Euston Rd., London NW1 2BU, United Kingdom. E-mail: jamshed.bomanji{at}uclh.nhs.uk

Our purpose was to compare the performance of ⁶⁸Ga-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-D-Phe¹,Tyr³-octreotate (DOTATATE), a novel selective somatostatin receptor 2 PET ligand, and ¹⁸F-FDG in the detection of pulmonary neuroendocrine tumors using PET/CT, with correlation of uptake and tumor grade on histology. Methods: The imaging findings of the first 18 consecutive patients (8 men and 10 women) with pulmonary neuroendocrine tumors (11 typical carcinoids, 2 atypical carcinoids, 1 large cell neuroendocrine tumor, 1 small cell neuroendocrine carcinoma, 1 non–small cell lung cancer with neuroendocrine differentiation, and 2 cases of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia) who underwent ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT were reviewed. In all cases, the diagnosis was established on histology. Results: Of 18 patients, 15 had primary tumors (median size, 2.7 cm; range, 0.5–8 cm) and 3 had recurrent tumors. All typical carcinoids showed high uptake of ⁶⁸Ga-DOTATATE (maximum standardized uptake value [SUV_max] 8.2), but 4 of 11 showed negative or minimal ¹⁸F-FDG uptake (SUV_max = 1.7–2.9). All tumors of higher grade showed high uptake of ¹⁸F-FDG (SUV_max 11.7), but 3 of 5 showed only minimal accumulation of ⁶⁸Ga-DOTATATE (SUV_max = 2.2–2.8). Neither case of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia showed uptake of ⁶⁸Ga-DOTATATE or ¹⁸F-FDG. Typical carcinoids showed significantly higher uptake of ⁶⁸Ga-DOTATATE and significantly less uptake of ¹⁸F-FDG than did tumors of higher grade (P = 0.002 and 0.005). There was no instance of false-positive uptake of ⁶⁸Ga-DOTATATE, but there were 3 sites of ¹⁸F-FDG uptake secondary to inflammation. ⁶⁸Ga-DOTATATE was superior to ¹⁸F-FDG in discriminating endobronchial tumor from distal collapsed lung (P = 0.02). Conclusion: Typical bronchial carcinoids showed higher and more selective uptake of ⁶⁸Ga-DOTATATE than of ¹⁸F-FDG. Atypical carcinoids and higher grades had less ⁶⁸Ga-DOTATATE avidity but were ¹⁸F-FDG–avid.

Key Words: neuroendocrine • PET/CT • ¹⁸F-FDG • ⁶⁸Ga-DOTATATE

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]